{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:46:03Z","timestamp":1773272763004,"version":"3.50.1"},"reference-count":42,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ERDF, POCI, Portugal 2020, FCT","award":["POCI-01-0145-FEDER-007274"],"award-info":[{"award-number":["POCI-01-0145-FEDER-007274"]}]},{"name":"NORTE 2020, Portugal 2020, ERDF","award":["NORTE-01-0145-FEDER-000003"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000003"]}]},{"name":"NORTE 2020, Portugal 2020, ERDF","award":["NORTE-07-0124-FEDER-000029"],"award-info":[{"award-number":["NORTE-07-0124-FEDER-000029"]}]},{"name":"ERDF, POCI, FCT","award":["POCI-01-0145-FEDER-016390"],"award-info":[{"award-number":["POCI-01-0145-FEDER-016390"]}]},{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["PTDC\/CTM-NAN\/120958\/2010"],"award-info":[{"award-number":["PTDC\/CTM-NAN\/120958\/2010"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["SFRH\/BD\/113031\/2015"],"award-info":[{"award-number":["SFRH\/BD\/113031\/2015"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["PD\/BD\/105976\/2014"],"award-info":[{"award-number":["PD\/BD\/105976\/2014"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"POPH-QREN, ESF, FCT, MCTES","award":["IF\/00615\/2013"],"award-info":[{"award-number":["IF\/00615\/2013"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>CD44v6-containing isoforms are frequently de novo expressed in gastric cancer (GC). Whether CD44v6 has a central role in GC transformation and\/or progression, whether it conditions response to therapy or whether it is only a bystander marker is still not known. Therefore, we aimed to clarify the role of CD44v6 in GC. We generated GC isogenic cell lines stably expressing CD44s or CD44v6 and tested them for different cancer hallmarks and response to cisplatin, and we further confirmed our findings in cells that endogenously express CD44v6. No correlation between overexpression of CD44v6 and the tested cancer hallmarks was observed, suggesting CD44v6 is not a driver of GC progression. Upon cisplatin treatment, CD44v6+ cells survive better and have lower apoptosis levels than CD44v6\u2212 cells, possibly due to concomitant activation of STAT3 and P38. In co-culture experiments, we discovered that CD44v6+ cells are involved in GC cell overgrowth after cisplatin treatment. In conclusion, we show that CD44v6 expression increases cell survival in response to cisplatin treatment in GC cells and that these cells override CD44v6-negative cells after cisplatin-treatment. This suggests that tumor expression of CD44v6-containing variants may condition the outcome of GC patients treated with chemotherapy.<\/jats:p>","DOI":"10.3390\/cancers12040858","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T11:57:14Z","timestamp":1585828634000},"page":"858","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Expression of CD44v6-Containing Isoforms Influences Cisplatin Response in Gastric Cancer Cells"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5892-0764","authenticated-orcid":false,"given":"Carla","family":"Pereira","sequence":"first","affiliation":[{"name":"i3S - Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"IPATIMUP - Institute of Molecular Pathology and Immunology, University of Porto, 4200-135 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9712-1460","authenticated-orcid":false,"given":"Daniel","family":"Ferreira","sequence":"additional","affiliation":[{"name":"i3S - Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"IPATIMUP - Institute of Molecular Pathology and Immunology, University of Porto, 4200-135 Porto, Portugal"},{"name":"INEB - Instituto de Engenharia Biom\u00e9dica, Universidade do Porto, 4200-180 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0570-2277","authenticated-orcid":false,"given":"Nuno","family":"Mendes","sequence":"additional","affiliation":[{"name":"i3S - Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"IPATIMUP - Institute of Molecular Pathology and Immunology, University of Porto, 4200-135 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2761-4929","authenticated-orcid":false,"given":"Pedro L.","family":"Granja","sequence":"additional","affiliation":[{"name":"i3S - Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"INEB - Instituto de Engenharia Biom\u00e9dica, Universidade do Porto, 4200-180 Porto, Portugal"},{"name":"ICBAS - Institute of Biomedical Sciences Abel Salazar, University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8712-7394","authenticated-orcid":false,"given":"Gabriela M.","family":"Almeida","sequence":"additional","affiliation":[{"name":"i3S - Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"IPATIMUP - Institute of Molecular Pathology and Immunology, University of Porto, 4200-135 Porto, Portugal"},{"name":"FMUP - Faculty of Medicine of the University of Porto, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8340-2264","authenticated-orcid":false,"given":"Carla","family":"Oliveira","sequence":"additional","affiliation":[{"name":"i3S - Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"IPATIMUP - Institute of Molecular Pathology and Immunology, University of Porto, 4200-135 Porto, Portugal"},{"name":"FMUP - Faculty of Medicine of the University of Porto, 4200-319 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/304030a0","article-title":"A cell-surface molecule involved in organ-specific homing of lymphocytes","volume":"304","author":"Gallatin","year":"1983","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.4049\/jimmunol.145.11.3589","article-title":"Triggering of the CD44 Antigen on Lymphocytes-T Promotes T-Cell Adhesion through the Lfa-1 Pathway","volume":"145","author":"Koopman","year":"1990","journal-title":"J. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.4049\/jimmunol.143.8.2457","article-title":"Dual Role of the CD44 Molecule in T-Cell Adhesion and Activation","volume":"143","author":"Shimizu","year":"1989","journal-title":"J. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/0092-8674(90)90694-A","article-title":"CD44 Is the Principal Cell-Surface Receptor for Hyaluronate","volume":"61","author":"Aruffo","year":"1990","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1083\/jcb.116.3.817","article-title":"Lymphocyte CD44 Binds the Cooh-Terminal Heparin-Binding Domain of Fibronectin","volume":"116","author":"Jalkanen","year":"1992","journal-title":"J. Cell Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1083\/jcb.107.5.1881","article-title":"The Function of Multiple Extracellular-Matrix Receptors in Mediating Cell-Adhesion to Extracellular-Matrix - Preparation of Monoclonal-Antibodies to the Fibronectin Receptor That Specifically Inhibit Cell-Adhesion to Fibronectin and React with Platelet Glycoproteins Ic-IIa","volume":"107","author":"Wayner","year":"1988","journal-title":"J. Cell Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1004","article-title":"CD44: From adhesion molecules to signalling regulators","volume":"4","author":"Ponta","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0065-230X(08)60101-3","article-title":"CD44: Structure, function, and association with the malignant process","volume":"71","author":"Naor","year":"1997","journal-title":"Adv. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1357-2725(97)00152-0","article-title":"The CD44 protein family","volume":"30","author":"Ponta","year":"1998","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.cellsig.2014.07.011","article-title":"Regulation of alternative splicing of CD44 in cancer","volume":"26","author":"Prochazka","year":"2014","journal-title":"Cell. Signal."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/bies.950170106","article-title":"CD44 Isoforms during Differentiation and Development","volume":"17","author":"Ruiz","year":"1995","journal-title":"Bioessays"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/labinvest.2010.155","article-title":"De novo expression of CD44 variants in sporadic and hereditary gastric cancer","volume":"90","author":"Oliveira","year":"2010","journal-title":"Lab. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.semcancer.2008.03.015","article-title":"Involvement of CD44, a molecule with a thousand faces, in cancer dissemination","volume":"18","author":"Naor","year":"2008","journal-title":"Semin. Cancer Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fcell.2017.00018","article-title":"CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells","volume":"5","author":"Senbanjo","year":"2017","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.5966\/sctm.2015-0048","article-title":"Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target","volume":"4","author":"Yan","year":"2015","journal-title":"Stem Cells Transl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.stem.2014.01.009","article-title":"CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis","volume":"14","author":"Todaro","year":"2014","journal-title":"Cell Stem Cell"},{"key":"ref_18","first-page":"235","article-title":"CD44, Hyaluronan, the Hematopoietic Stem Cell, and Leukemia-Initiating Cells","volume":"6","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.18632\/oncotarget.3241","article-title":"Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6\/STAT3\/Jagged-1\/Notch positive feedback loop","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10549-015-3414-3","article-title":"CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells","volume":"151","author":"Boulbes","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"9313","DOI":"10.18632\/oncotarget.3220","article-title":"Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer","volume":"6","author":"Gao","year":"2015","journal-title":"Oncotarget"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"15862","DOI":"10.1074\/jbc.M110.208421","article-title":"CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance","volume":"286","author":"Jung","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/pros.22775","article-title":"CD44 variant 6 is associated with prostate cancer metastasis and chemo-\/radioresistance","volume":"74","author":"Ni","year":"2014","journal-title":"Prostate"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"8811","DOI":"10.1007\/s13277-015-4755-6","article-title":"Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells","volume":"37","author":"Lv","year":"2016","journal-title":"Tumour Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.21873\/anticanres.12969","article-title":"Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression","volume":"38","author":"Miyoshi","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.biopha.2014.08.001","article-title":"The prognostic value of CD44 expression in gastric cancer: A meta-analysis","volume":"68","author":"Chen","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s00432-015-1964-8","article-title":"Evaluation of the prognostic value and functional roles of CD44v6 in gastric cancer","volume":"141","author":"Xie","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"45848","DOI":"10.18632\/oncotarget.17435","article-title":"Regulation of CD44v6 expression in gastric carcinoma by the IL-6\/STAT3 signaling pathway and its clinical significance","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Pereira, C., Ferreira, D., Lemos, C., Martins, D., Mendes, N., Almeida, D., Granja, P., Carneiro, F., Almeida, R., and Almeida, G.M. (2018). CD44v6 expression is a novel predictive marker of therapy response and poor prognosis in gastric cancer patients. bioRxiv, 468934.","DOI":"10.1101\/468934"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jocn.2016.05.012","article-title":"The role of CD44 in glioblastoma multiforme","volume":"34","author":"Mooney","year":"2016","journal-title":"J. Clin. Neurosci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"12866","DOI":"10.18632\/oncotarget.14163","article-title":"CD44v6 overexpression related to metastasis and poor prognosis of colorectal cancer: A meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_32","first-page":"41","article-title":"CD44 variant 6 expression predicts response to treatment in advanced colorectal cancer","volume":"11","author":"Bendardaf","year":"2004","journal-title":"Oncol. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Wu, C.J., Sundararajan, V., Sheu, B.C., Huang, R.Y., and Wei, L.H. (2020). Activation of STAT3 and STAT5 Signaling in Epithelial Ovarian Cancer Progression: Mechanism and Therapeutic Opportunity. Cancers, 12.","DOI":"10.3390\/cancers12010024"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.canlet.2013.08.022","article-title":"Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer","volume":"341","author":"Ji","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"109135","DOI":"10.1016\/j.biopha.2019.109135","article-title":"Targeting STAT3 inhibition to reverse cisplatin resistance. Biomed","volume":"117","author":"Sun","year":"2019","journal-title":"Pharmacother"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/emmm.201302732","article-title":"Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK","volume":"5","author":"Pereira","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"ref_37","first-page":"3819","article-title":"Phosphorylation of STAT3 in head and neck cancer requires p38 MAPKinase, whereas phosphorylation of STAT1 occurs via a different signaling pathway","volume":"31","author":"Riebe","year":"2011","journal-title":"Anticancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.oraloncology.2007.10.009","article-title":"Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma","volume":"44","author":"Riechelmann","year":"2008","journal-title":"Oral Oncol."},{"key":"ref_39","first-page":"91","article-title":"Establishment and characterization of two cell lines derived from human diffuse gastric carcinomas xenografted in nude mice","volume":"428","author":"David","year":"1996","journal-title":"Virchows Arch."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/ejhg.2013.292","article-title":"Rescue of wild-type E-cadherin expression from nonsense-mutated cancer cells by a suppressor-tRNA","volume":"22","author":"Ferreira","year":"2014","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s10120-013-0249-7","article-title":"Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase","volume":"17","author":"Nakamura","year":"2014","journal-title":"Gastric Cancer"},{"key":"ref_42","first-page":"421","article-title":"N:NIH(S)-nu\/nu mice with combined immunodeficiency: A new model for human tumour heterotransplantation","volume":"65","author":"Azar","year":"1980","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/4\/858\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:14:36Z","timestamp":1760174076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/4\/858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,2]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["cancers12040858"],"URL":"https:\/\/doi.org\/10.3390\/cancers12040858","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,2]]}}}